Orforglipron: what is legal, and what is being sold
The short answer
Orforglipron is FDA-approved in the United States, so the drug itself is legal to prescribe. It is also not on the 503A Bulks List, which is what governs whether a pharmacy may compound its own version — and that is the question worth asking here, as of 2026-08-29. The Pharmacy Compounding Advisory Committee has never considered it, so there is no vote to report — it is investigational, and the routes to it are set out below.
What FDA actually evaluated
FDA assessed Orforglipron for one thing: chronic weight management alongside a reduced-calorie diet and increased physical activity, in adults with obesity or with overweight plus at least one weight-related comorbidity..
Any use outside that labelled population, and any product not supplied as the approved tablet.
Full regulatory status
| FDA-approved drug? | Yes. FDA approved Foundayo (orforglipron) on 1 April 2026, the first new molecular entity cleared under the Commissioner's National Priority Voucher pilot. It is a once-daily oral tablet rather than an injection, which is what makes it different from everything else on this page. |
|---|---|
| What has been evaluated | Chronic weight management alongside a reduced-calorie diet and increased physical activity, in adults with obesity or with overweight plus at least one weight-related comorbidity. |
| PCAC recommendation | Never considered — no nomination has reached the committee |
| FDA reviewers' position | Not applicable. Orforglipron is an approved drug and has never been before the Pharmacy Compounding Advisory Committee. |
| Category 2 status | Not applicable. Orforglipron is an approved drug and is not on the 503A Bulks List. |
| 503A Bulks List today | Not on the 503A Bulks List. Because an approved product is commercially available, section 503A(b)(1)(D) bars a pharmacy from regularly compounding what is essentially a copy of it. Orforglipron has never been in shortage, so the relaxation that once applied to semaglutide and tirzepatide has never applied here at all. |
| 503B status | Not on the 503B Bulks List, and there has been no shortage-based route for outsourcing facilities. |
| Prescription status | Prescription-only. The lawful route is the approved Foundayo tablet, dispensed by a pharmacy against a prescription. |
| Next federal event | No scheduled federal event. As a 2026 approval, post-marketing safety reporting and any labelling changes are what to watch. |
If you compete in sport
No substance-specific WADA determination for orforglipron was located. That means none was found, not that it is permitted.
We could not find a substance-specific ruling. Treat this as unknown, not as permission, and check with your governing body before use.
Why FDA's own reviewers recommended against it
What you can actually do today
Orforglipron is new enough that the grey market has not fully formed around it, and being an oral small molecule rather than a peptide makes it a harder counterfeit target than semaglutide. Sites offering “research use only” orforglipron do exist. We have NOT found an FDA warning letter naming compounded or research-grade orforglipron, and that is recorded as an open question rather than implied enforcement that has not happened. What FDA has said about GLP-1 products sold outside the approved supply chain applies to it by the same reasoning.
What would have to happen for this to change
- 1FDA completes its own evaluation. The advisory vote is non-binding — FDA can accept or reject it.
- 2FDA publishes a proposed rule in the Federal Register identifying substances proposed for inclusion or exclusion, with its reasoning.
- 3A public comment period opens. Anyone may submit evidence and scientific or legal objections.
- 4FDA reviews the comments and the administrative record.
- 5FDA publishes a final rule, or withdraws or modifies the proposal.
- 6The final rule takes effect and amends the list at 21 CFR 216.23.
Sources
- Drugs@FDA — Foundayo (openFDA)
- FDA — approves first new molecular entity under the National Priority Voucher program
- FDA — Novel Drug Approvals for 2026
- FDA — FD&C Act provisions that apply to human drug compounding
- FDA — intends to take action against non-FDA-approved GLP-1 drugs, 6 Feb 2026
See the status of all seven peptides side by side in the FDA 503A compounding tracker. Or read our full guide to Orforglipron.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.